FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3020365538> ?p ?o ?g. }

• W3020365538 endingPage "228" @default.
• W3020365538 startingPage "223" @default.
• W3020365538 abstract "Purpose The purpose of this study was to compare the neovascularization inhibiting the effect of topical bevacizumab and sorafenib and to determine the effective dose of sorafenib.Material and Methods Forty-two healthy Wistar albino rats were randomly divided into six groups. The right corneas of all rats except group 1 were cauterised with silver nitrate. Group 2 received DMSO, group 3 received topical bevacizumab (5 mg/dL, 3 times a day) and group 4, 5 and 6 received topical sorafenib (2.5 mg/dl, 5 mg/dL, 7.5 mg/dL, 2 times a day respectively), between days 1 and 7. Corneal photographs were taken on day 8 and the corneal neovascular area percentage was calculated. Following decapitation, the corneas were removed to determine the levels of VEGF ELİSA and corneal immune staining. The Mann–Whitney U-test was used for statistical analysisResults The neovascular corneal area percentage was statistically significantly lower in the treatment groups than group 2 (p < 0.05). The intensity of VEGF immune staining was also lower in groups 3, 5 and 6 from the group 2. Group 3, 5 and 6 were no significant differences compared to group 1. The VEGF ELİSA levels were statistically significantly lower in group 3, 5 and 6 compared to group 2 (p < 0.05). There was no statistically difference between VEGF ELİSA levels of group 2 and 4 (p > 0.05)Conclusions Sorafenib was as effective as bevacizumab in the regression of corneal neovascularization. The effect of sorafenib seems to be dose-dependent. The low doses and twice a day administration are important advantages of sorafenib." @default.
• W3020365538 created "2020-05-01" @default.
• W3020365538 creator A5001202431 @default.
• W3020365538 creator A5006588049 @default.
• W3020365538 creator A5025306006 @default.
• W3020365538 creator A5039672518 @default.
• W3020365538 creator A5091261009 @default.
• W3020365538 date "2020-05-13" @default.
• W3020365538 modified "2023-10-18" @default.
• W3020365538 title "Comparison of the effect of topical bevacizumab and sorafenib in experimental corneal neovascularization" @default.
• W3020365538 cites W1560725142 @default.
• W3020365538 cites W1963487295 @default.
• W3020365538 cites W1965569697 @default.
• W3020365538 cites W1967821317 @default.
• W3020365538 cites W1969933921 @default.
• W3020365538 cites W1970189151 @default.
• W3020365538 cites W1982880540 @default.
• W3020365538 cites W1985147506 @default.
• W3020365538 cites W2000307014 @default.
• W3020365538 cites W2003092321 @default.
• W3020365538 cites W2010392784 @default.
• W3020365538 cites W2010899791 @default.
• W3020365538 cites W2011842892 @default.
• W3020365538 cites W2021780953 @default.
• W3020365538 cites W2024119736 @default.
• W3020365538 cites W2032940048 @default.
• W3020365538 cites W2036983320 @default.
• W3020365538 cites W2037327534 @default.
• W3020365538 cites W2040116142 @default.
• W3020365538 cites W2042186177 @default.
• W3020365538 cites W2053926496 @default.
• W3020365538 cites W2071980849 @default.
• W3020365538 cites W2081033328 @default.
• W3020365538 cites W2098582960 @default.
• W3020365538 cites W2129331774 @default.
• W3020365538 cites W2163539442 @default.
• W3020365538 cites W2330686299 @default.
• W3020365538 cites W2417039652 @default.
• W3020365538 cites W2808315624 @default.
• W3020365538 cites W2951711447 @default.
• W3020365538 cites W51564482 @default.
• W3020365538 doi "https://doi.org/10.1080/15569527.2020.1760877" @default.
• W3020365538 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32338080" @default.
• W3020365538 hasPublicationYear "2020" @default.
• W3020365538 type Work @default.
• W3020365538 sameAs 3020365538 @default.
• W3020365538 citedByCount "7" @default.
• W3020365538 countsByYear W30203655382020 @default.
• W3020365538 countsByYear W30203655382021 @default.
• W3020365538 countsByYear W30203655382022 @default.
• W3020365538 countsByYear W30203655382023 @default.
• W3020365538 crossrefType "journal-article" @default.
• W3020365538 hasAuthorship W3020365538A5001202431 @default.
• W3020365538 hasAuthorship W3020365538A5006588049 @default.
• W3020365538 hasAuthorship W3020365538A5025306006 @default.
• W3020365538 hasAuthorship W3020365538A5039672518 @default.
• W3020365538 hasAuthorship W3020365538A5091261009 @default.
• W3020365538 hasConcept C118487528 @default.
• W3020365538 hasConcept C126322002 @default.
• W3020365538 hasConcept C141071460 @default.
• W3020365538 hasConcept C167734588 @default.
• W3020365538 hasConcept C2776694085 @default.
• W3020365538 hasConcept C2776882836 @default.
• W3020365538 hasConcept C2777025900 @default.
• W3020365538 hasConcept C2777802072 @default.
• W3020365538 hasConcept C2777844972 @default.
• W3020365538 hasConcept C2778019345 @default.
• W3020365538 hasConcept C2778271429 @default.
• W3020365538 hasConcept C2778695046 @default.
• W3020365538 hasConcept C2780394083 @default.
• W3020365538 hasConcept C71924100 @default.
• W3020365538 hasConceptScore W3020365538C118487528 @default.
• W3020365538 hasConceptScore W3020365538C126322002 @default.
• W3020365538 hasConceptScore W3020365538C141071460 @default.
• W3020365538 hasConceptScore W3020365538C167734588 @default.
• W3020365538 hasConceptScore W3020365538C2776694085 @default.
• W3020365538 hasConceptScore W3020365538C2776882836 @default.
• W3020365538 hasConceptScore W3020365538C2777025900 @default.
• W3020365538 hasConceptScore W3020365538C2777802072 @default.
• W3020365538 hasConceptScore W3020365538C2777844972 @default.
• W3020365538 hasConceptScore W3020365538C2778019345 @default.
• W3020365538 hasConceptScore W3020365538C2778271429 @default.
• W3020365538 hasConceptScore W3020365538C2778695046 @default.
• W3020365538 hasConceptScore W3020365538C2780394083 @default.
• W3020365538 hasConceptScore W3020365538C71924100 @default.
• W3020365538 hasIssue "3" @default.
• W3020365538 hasLocation W30203655381 @default.
• W3020365538 hasOpenAccess W3020365538 @default.
• W3020365538 hasPrimaryLocation W30203655381 @default.
• W3020365538 hasRelatedWork W2028256742 @default.
• W3020365538 hasRelatedWork W2069153798 @default.
• W3020365538 hasRelatedWork W2285542579 @default.
• W3020365538 hasRelatedWork W2326575636 @default.
• W3020365538 hasRelatedWork W2353130325 @default.
• W3020365538 hasRelatedWork W2378726502 @default.
• W3020365538 hasRelatedWork W2381070537 @default.
• W3020365538 hasRelatedWork W2516101716 @default.
• W3020365538 hasRelatedWork W3030897015 @default.

• next